Royal Bank Of Canada Sab Biotherapeutics, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.62 - $1.0 $3,116 - $5,026	-5,026 Reduced 98.67%	68 $0
Q3 2023 Nov 14, 2023	SELL	$0.47 - $0.9 $128 - $246	-274 Reduced 5.1%	5,094 $3,000
Q2 2023 Aug 14, 2023	BUY	$0.38 - $1.09 $208 - $597	548 Added 11.37%	5,368 $4,000
Q4 2022 Feb 14, 2023	SELL	$0.54 - $9.8 $161 - $2,930	-299 Reduced 5.84%	4,820 $2,000
Q3 2022 Nov 14, 2022	BUY	$0.13 - $12.4 $38 - $3,707	299 Added 6.2%	5,119 $3,000
Q1 2022 May 16, 2022	BUY	$1.78 - $8.5 $5,019 - $23,970	2,820 Added 141.0%	4,820 $18,000
Q4 2021 Feb 14, 2022	BUY	$7.3 - $11.24 $14,600 - $22,480	2,000 New	2,000 $16,000

529K

Ticker SABS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,030,900
Market Cap $132M
Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.